AHA today submitted comments to the House Health Care Innovation Caucus in response to a request for feedback regarding innovative policy ideas that improve quality of care and lower costs for consumers. “Based on our members’ experience with designing, implementing and scaling value-based payment arrangements, we believe that certain principles should apply across all value-based projects and models,” AHA said. Specifically, AHA said value-based models should be designed transparently and evaluated holistically, promote fully integrated care, balance risk versus reward, waive fraud and abuse laws and regulations that inhibit care coordination, provide timely access to data and adequate risk adjustment, minimize regulatory burden, and leverage partnerships where appropriate. AHA also encouraged the caucus to limit model measures to what matters, standardize quality metrics and reporting platforms across programs and models, and integrate strategies to make care more affordable. Reps. Mike Kelly (R-PA), Ron Kind (D-WI), Markwayne Mullin (R-OK) and Ami Bera (D-CA) launched the caucus in March to explore and advance innovative payment models and technologies.
 

Related News Articles

Perspective
Public
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Perspective
Public
Personalized cancer vaccines that are tailored to individual patients, targeting the specific mutations present in their tumors.AI analysis of pathology slides…
Headline
The Centers for Medicare & Medicaid Services June 27 announced the rollout of a 6-year technology-enabled prior authorization program pilot. Through…
Headline
The AHA today launched the new Care Delivery Transformation Framework that aims to support hospitals and health systems with tools and resources for the…
Perspective
Patient-centered care strategies and models that emphasize the importance of understanding and responding to patient preferences, needs and values. More care…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…